
Sling Therapeutics, a clinical-stage biopharmaceutical company, has raised $123 million in Series C funding to advance its oral treatment for thyroid eye disease (TED).
The round was led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management.
Sling Therapeutics will use the funding to support the clinical development of linsitinib, an oral small-molecule drug designed to target IGF-1R, a protein involved in TED.
“This financing reinforces our conviction in linsitinib’s potential to transform the treatment landscape for people living with TED as the first and only oral IGF-1R inhibitor in late-stage development,” said Ryan Zeidan, Ph.D., President and Chief Executive Officer of Sling Therapeutics. “The data generated to date give us confidence in linsitinib’s potential to meaningfully address important limitations of current TED therapies and offer patients an effective, convenient oral treatment option that could be used earlier and more broadly in the treatment journey. With the support of a high-quality investor syndicate, we are well positioned to advance linsitinib toward commercialization with urgency and purpose for the TED community.”
The company has started the global Phase 3 ORBIT trial to evaluate linsitinib in adults with moderate-to-severe active TED.
“Sling has demonstrated compelling clinical progress with linsitinib, supporting its potential to become an important new treatment option for patients with TED,” said Regina Salvat, Ph.D., Partner at Forbion. “TED can have a devastating physical and emotional impact on patients, and we believe there remains a significant unmet need for therapies that combine compelling efficacy with improved convenience and tolerability. We are proud to support Sling’s next phase of growth as the company advances what could become the first oral IGF-1R therapy for TED.”
“Linsitinib offers the combination of a validated target, a differentiated safety profile, and the convenience advantage of an oral therapy for patients who currently face invasive surgery or lengthy infusion regimens,” said Peter Bojo, Principal at TPG Life Sciences Innovations. “Our continued investment into Sling reflects our confidence in the team’s execution and in linsitinib’s potential to meaningfully improve the treatment paradigm for TED patients. We’re pleased to deepen our commitment to the company as it remains focused on delivering what could be a transformative option for TED patients.”
Linsitinib has been studied in more than 900 patients across 15 clinical trials for multiple diseases and has received Fast Track Designation from the U.S. FDA.
Sling Therapeutics is based in Ann Arbor, Michigan, and is led by CEO Ryan Zeidan.